Skip to main content
. Author manuscript; available in PMC: 2021 Aug 21.
Published in final edited form as: ACS Chem Biol. 2020 Jul 13;15(8):2079–2086. doi: 10.1021/acschembio.0c00222

Figure 3.

Figure 3.

C8 Alkyl Cysteine Inhibits Oncogenic RAS Signaling in NRAS-Mutated Melanoma Cells Compared to BRAF-Mutated Melanoma Cells. (a) Western blot of six different treatment conditions in the WM3000 melanoma cell line with the NRAS Q61R mutation. Treatment conditions include the untreated control (C), vehicle control (20 μM TCEP in DMSO) (V), 10 μM C8 alkyl serine (2), 10 μM C8 alkyl cysteine (1), 10 μM 2-bromopalmitate (2-BP), and 12 nM binimetinib (BM). (b,c) Western blot lanes for p-AKT and p-ERK were analyzed and quantified using ImageJ. Each treatment condition was normalized to the vehicle control. Results are the mean ± s.d. of three independent experiments. *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005 (one-way ANOVA). (d) Western blot of the six different treatment conditions in the Sk-Mel-28 melanoma cell line with the BRAF V600E mutation. (e,f) Western blot lanes for p-AKT and p-ERK were analyzed and quantified using ImageJ. Each treatment condition was normalized to the vehicle control. Results are the mean ± s.d. of three independent experiments. *p ≤ 0.05 (one-way ANOVA).